Details werden geladen...
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | The Manila Times
Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring (CBGM) technology
Ähnliche Seiten
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | The Manila Times
https://www.manilatimes.net/2026/03/31/tmt-newswire/globenewswire/glucotrack-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-highlights/2310937Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | The Manila Times
https://www.manilatimes.net/2026/05/15/tmt-newswire/globenewswire/sangamo-therapeutics-reports-recent-business-highlights-and-first-quarter-2026-financial-results/2344381Damora Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | The Manila Times
https://www.manilatimes.net/2026/05/13/tmt-newswire/globenewswire/damora-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights/2342304Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times
https://www.manilatimes.net/2026/05/11/tmt-newswire/globenewswire/dyne-therapeutics-reports-first-quarter-2026-financial-results-and-recent-business-highlights/2340634Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights | The Manila Times
https://www.manilatimes.net/2026/05/07/tmt-newswire/globenewswire/shattuck-labs-reports-first-quarter-2026-financial-results-and-recent-business-highlights/2338148